{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:52:31Z","timestamp":1765486351071},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"18","license":[{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To summarize the current literature on the use and clinical efficacy of extended-infusion (EI) beta-lactam antibiotics, including piperacillin\u2013tazobactam, meropenem, and cefepime.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Gram-negative infections are a serious concern among hospitalized patients and require innovative pharmacokinetic dosing strategies to achieve clinical success, especially as the emergence of resistant gram-negative pathogens has outpaced the development of new antibiotics. Beta-lactam antibiotics exhibit time-dependent activity, which means that optimal efficacy is achieved when free drug concentrations stay above the minimum inhibitory concentration for an extended duration of the recommended dosage interval. EI piperacillin\u2013tazobactam therapy has demonstrated improved clinical outcomes and decrease mortality in critically ill patients with gram-negative infections, particularly Pseudomonas aeruginosa infections. EI meropenem has shown higher therapeutic success rates for patients with febrile neutropenia and shorter intensive care unit (ICU) length of stay (LOS) with a reduction in ventilator days in patients with multidrug-resistant ventilator-associated pneumonia. However, a larger study showed no difference in clinical outcomes between standard-infusion and EI meropenem. EI cefepime has been associated with decreased mortality and shorter ICU LOS in patients with Pseudomonas aeruginosa infections. Common challenges associated with EI beta-lactam antibiotics include Y-site incompatibilities, lack of intravenous access, and tubing residuals. It is important to note that factors such as diverse patient populations and study methodology, along with various antibiotic dose regimens, may have contributed to conflicting data on EI beta-lactam therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Based on most published literature, there appears to be a favorable trend toward use of EI beta-lactam therapy in clinical practice, particularly in critically ill patients with gram-negative infections.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ajhp\/zxz154","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T05:05:10Z","timestamp":1567487110000},"page":"1383-1394","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics"],"prefix":"10.1093","volume":"76","author":[{"given":"Melanie","family":"Chen","sequence":"first","affiliation":[{"name":"Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Buurma","sequence":"additional","affiliation":[{"name":"Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Monmouth Medical Center, Long Branch, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Germin","family":"Fahim","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, and Department of Pharmacy, Monmouth Medical Center, Long Branch, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"key":"2019091013195164800_CIT0001","doi-asserted-by":"crossref","first-page":"VMBF-0016-2015","DOI":"10.1128\/microbiolspec.VMBF-0016-2015","article-title":"Mechanisms of antibiotic resistance","volume":"4","author":"Munita","year":"2016","journal-title":"Microbiol Spectr"},{"key":"2019091013195164800_CIT0002","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/14787210.2017.1348894","article-title":"Extended infusion of beta-lactam antibiotics: optimizing therapy in critically-ill patients in the era of antimicrobial resistance","volume":"15","author":"Rizk","year":"2017","journal-title":"Expert Rev Anti Infect Ther."},{"key":"2019091013195164800_CIT0003","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1592\/phco.31.8.767","article-title":"The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study","volume":"31","author":"Yost","year":"2011","journal-title":"Pharmacotherapy."},{"key":"2019091013195164800_CIT0004","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/j.clinthera.2012.11.005","article-title":"Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients","volume":"34","author":"Lee","year":"2012","journal-title":"Clin Ther."},{"key":"2019091013195164800_CIT0005","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4103\/sja.SJA_148_17","article-title":"Effect of extended infusion of meropenem and nebulized amikacin on gram-negative multidrug-resistant ventilator-associated pneumonia","volume":"12","author":"Ammar","year":"2018","journal-title":"Saudi J Anaesth."},{"key":"2019091013195164800_CIT0006","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1128\/AAC.02365-12","article-title":"Extended-infusion cefepime reduces mortality in patients with pseudomonas aeruginosa infections","volume":"57","author":"Bauer","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"2019091013195164800_CIT0007","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1016\/j.clinthera.2009.11.026","article-title":"Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia","volume":"31","author":"Kim","year":"2009","journal-title":"Clin Ther"},{"key":"2019091013195164800_CIT0008","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1345\/aph.1R523","article-title":"Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study","volume":"47","author":"Arnold","year":"2013","journal-title":"Ann Pharmacother."},{"key":"2019091013195164800_CIT0009","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1177\/1060028015579427","article-title":"Clinical and economic impact of empirical extended-infusion piperacillin-tazobactam in a community medical center","volume":"49","author":"Brunetti","year":"2015","journal-title":"Ann Pharmacother."},{"key":"2019091013195164800_CIT0010","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1310\/hpj4905-444","article-title":"Administration of extended infusion piperacillin-tazobactam with the use of smart pump technology","volume":"49","author":"Maddox","year":"2014","journal-title":"Hosp Pharm."},{"key":"2019091013195164800_CIT0011","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/510590","article-title":"Piperacillin-tazobactam for pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy","volume":"44","author":"Lodise","year":"2007","journal-title":"Clin Infect Dis."},{"key":"2019091013195164800_CIT0012","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1093\/jac\/dku150","article-title":"Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study","volume":"69","author":"Feh\u00e9r","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"2019091013195164800_CIT0013","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/1078155216687151","article-title":"Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia","volume":"24","author":"Wrenn","year":"2018","journal-title":"J Oncol Pharm Pract."},{"key":"2019091013195164800_CIT0014","volume-title":"Medication administration: extended-infusion meropenem protocol","year":"2016"},{"key":"2019091013195164800_CIT0015","volume-title":"Medication administration: extended-infusion cefepime protocol","year":"2016"},{"key":"2019091013195164800_CIT0016","volume-title":"Medication administration: extended-infusion piperacillin\/tazobactam protocol","year":"2016"},{"key":"2019091013195164800_CIT0017","volume-title":"Pharmacokinetic\/pharmacodynamic dose optimization of antibiotics (beta-lactams, aminoglycosides, and ciprofloxacin) for the treatment of gram-negative infections","author":"Berti","year":"2017"},{"key":"2019091013195164800_CIT0018","volume-title":"JMH extended infusion piperacillin\/tazobactam protocol","author":"Fries","year":"2010"},{"key":"2019091013195164800_CIT0019","volume-title":"Extended infusions (pharmacodynamic dosing) of piperacillin\/tazobactam and meropenem-adult guidelines","year":"2009"},{"key":"2019091013195164800_CIT0020","volume-title":"Department of pharmacy dosage adjustment protocol","year":"2018"},{"key":"2019091013195164800_CIT0021","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2146\/ajhp140369","article-title":"Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion","volume":"72","author":"Berti","year":"2015","journal-title":"Am J Health-Syst Pharm."},{"key":"2019091013195164800_CIT0022","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1345\/aph.1R721","article-title":"Using higher doses to compensate for tubing residuals in extended-infusion piperacillin-tazobactam","volume":"47","author":"Lam","year":"2013","journal-title":"Ann Pharmacother."},{"key":"2019091013195164800_CIT0023","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.diagmicrobio.2009.03.002","article-title":"Outcomes of extended infusion piperacillin\/tazobactam for documented gram-negative infections","volume":"64","author":"Patel","year":"2009","journal-title":"Diagn Microbiol Infect Dis."},{"key":"2019091013195164800_CIT0024","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/jac\/dkv288","article-title":"Is prolonged infusion of piperacillin\/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic\/pharmacodynamic and patient outcomes? An observation from the defining antibiotic levels in intensive care unit patients (DALI) cohort","volume":"71","author":"Abdul-Aziz","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"2019091013195164800_CIT0025","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13613-017-0296-z","article-title":"Emergence of antimicrobial resistance to pseudomonas aeruginosa in the intensive care unit: association with the duration of antibiotic exposure and mode of administration","volume":"7","author":"Yusuf","year":"2017","journal-title":"Ann Intensive Care."},{"key":"2019091013195164800_CIT0026","author":"Vela","year":"2016"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/76\/18\/1383\/29514853\/zxz154.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T06:47:40Z","timestamp":1575614860000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/76\/18\/1383\/5558387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":26,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2019,9,3]]},"published-print":{"date-parts":[[2019,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxz154","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9,15]]},"published":{"date-parts":[[2019,9,3]]}}}